Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00023374 · ClinicalTrials.gov registry record · NA

TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance

A NA study of Tuberculosis, sponsored by Centers for Disease Control and Prevention.

Completed
Registry status
NA
Development phase
98
Enrollment target
20
Study locations

NCT00023374 is a NA study of Tuberculosis that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 98 participants, below the 931-participant average among 29 other Tuberculosis trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00023374, a NA study of Tuberculosis, has completed, sponsored by Centers for Disease Control and Prevention.

COMPLETED
Registry status
NA
Development phase
98 participants
Enrollment target
20
Study locations

Study Summary

This study is a prospective, open-label, nonrandomized trial using a largely-intermittent, six-month tuberculosis treatment regimen among patients who will not receive isoniazid due to the presence of initial isoniazid resistance or intolerance. Subjects are enrolled after resistance or intolerance to isoniazid has been documented, and are treated for a total of six months (nine months if baseline chest x-ray shows cavitation and 2-month sputum culture is positive) with twice weekly or thrice weekly rifampin, ethambutol, and pyrazinamide.

Conditions Studied

Tuberculosis

Interventions

  • DRUG Ethambutol
  • DRUG Rifampin
  • DRUG Pyrazinamide
  • DRUG REZ

Study Locations (20)

New York

  • New York University School of Medicine - New York
  • Columbia University/Presbyterian Medical Center - New York
  • Harlem Hospital Center - New York

Texas

  • University of North Texas Health Science Center - Fort Worth
  • Thomas Street Clinic - Houston
  • Audi L. Murphy VA Hospital - San Antonio

California

  • LA County/USC Medical Center - Los Angeles
  • University of California, San Francisco - San Francisco

Illinois

  • Chicago VA Medical Center (Lakeside) - Chicago
  • Hines VA Medical Center - Hines

North Carolina

  • Carolinas Medical Center - Charlotte
  • Duke University Medical Center - Durham

Arkansas

  • Central Arkansas Veterans Health System - Little Rock

Colorado

  • Denver Department of Public Health and Hospitals - Denver

District of Columbia

  • Washington, D.C. VAMC - Washington D.C.

Trial Details

FieldValue
Enrollment Target 98 participants
Start Date 2000-08
Est. Completion 2010-12
Phase NA

Sponsor

Centers for Disease Control and Prevention

139 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00023374

The ClinicalTrials.gov registry entry for NCT00023374 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 931-participant average among 29 other Tuberculosis trials with a reported enrollment target (89% lower). The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Tuberculosis appearing as the primary indexed condition, and to 4 interventions - of which Ethambutol is the first listed.

NCT00023374 reports 20 study locations spanning 13 distinct geographic areas - top geographies include New York, Texas, California.

Frequently Asked Questions

What is clinical trial NCT00023374 about?

NCT00023374 is a clinical study titled "TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance". This study is a prospective, open-label, nonrandomized trial using a largely-intermittent, six-month tuberculosis treatment regimen among patients who will not receive isoniazid due to the presence of initial isoniazid resistance or intolerance. Subjects are enrolled after resistance or intolerance ...

What is the current status of trial NCT00023374?

This trial is currently completed. It is a NA study. The enrollment target is 98 participants. The study started on 2000-08. Estimated completion is 2010-12.

What conditions does trial NCT00023374 study?

This clinical trial studies the following conditions: Tuberculosis.

What interventions are being tested in trial NCT00023374?

The interventions under investigation include: Ethambutol (DRUG), Rifampin (DRUG), Pyrazinamide (DRUG), REZ (DRUG).

Who is sponsoring clinical trial NCT00023374?

This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00023374 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Tuberculosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Tuberculosis

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.